



THOMSON REUTERS RESEARCH BY DISEASE CATEGORY

A Select List of Recently Published Work by Thomson Reuters Researchers

Since 1988, researchers at Thomson Reuters have conducted studies of disease progression, treatment patterns, health outcomes, and their associated costs to patients, employers, health plans, and the government. Since 2000, these studies have resulted in over 300 peer-reviewed articles published in leading journals, which have made a substantial contribution to the body of literature used to formulate policy decisions and improve healthcare for Americans.

Authors in bold typeface are (or were at the time the work was written) Thomson Reuters staff.

CONTENTS

Anemia	1
Autoimmune Diseases	2
Cardiovascular	2
Depression	5
Diabetes and Metabolic	6
Drug Spending	8
Health and Productivity Management	9
Infectious Diseases	14
Men’s Health	15
Mental Health	16
Neurology and Pain	18
Oncology	19
Respiratory	21
Schizophrenia and Bipolar	22
Skin Diseases	23
Substance Abuse	24
Women’s Health	26
Other	27



Anemia

- Song X, Long SR, Marder WD, Sullivan SD, Kallich J.** The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. *Annals of Pharmacotherapy* 2009; 43(7): 1203–10.
- Wish J, **Schulman K**, Law A, Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: A retrospective claims database analysis. *Kidney and Blood Pressure Research* 2009; 32(2): 110–118.
- Wish JB, Nassar GM, **Schulman K**, del Aguila M, Provenzano R. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. *Clinical Nephrology* 2008; 69(4): 251–9.
- Gosselin A, Pashos CL, Harley C, **Mark TL**, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies. *Clinical Therapeutics* 2006; 28(10): 1701–09.
- Berndt E, **Crown W**, Kallich J, **Long S, Song X**, Lyman GH. The impact of anaemia and its treatment on employee disability and medical costs. *Pharmacoeconomics* 2005; 23(2): 183–192.
- Duh MS, **Mark TL**. Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy related anemia. *Expert Review of Pharmacoeconomics and Outcomes Research* 2005; 5(4): 383–394.
- Lyman GH, Berndt ER, Kallich JD, Erder MH, **Crown WH, Long SR**, Lee H, **Song X**, Finkelstein SN. The economic burden of anemia in cancer patients receiving chemotherapy. *Value in Health* 2005; 8(2): 149–156.
- Mark TL**, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. *Current Medical Research and Opinion* 2005; 21(9): 1347–1354.
- Papatheofanis F, Fahrbach K, **Mark TL**, Chiang T, Frame D, Suruki RY, Scheye R, Drielick M, Nalysnyk L. A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents. *Journal of Clinical Oncology* 2004; 22(14S): 6114.
- Berndt E, **Crown W**. Labor force activity in cancer patients with anemia. *Quality of Life in Oncology* 2002; 5(4): 10–13.



Autoimmune Diseases

Carls G, Li T, Panopalis P, **Wang S**, **Mell AG**, **Gibson TB**, **Goetzel RZ**. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. *Journal of Occupational and Environmental Medicine* 2009; 51(1): 66–79.

Li T, **Carls GS**, Panopalis P, **Wang S**, **Gibson TB**, **Goetzel RZ**. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A five-year analysis of a large Medicaid population. *Arthritis and Rheumatism* 2009; 61(6): 755–763.

Curkendall SM, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois, RW. Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter? *Arthritis and Rheumatism* 2008; 59(10): 1519–26.

Gibson TB, Ng E, **Ozminkowski RJ**, **Wang S**, Burton WN, **Goetzel RZ**, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. *Journal of Occupational and Environmental Medicine* 2008; 50(11): 1261–1272.

Hochberg MC, **Johnston SS**, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. *Current Medical Research and Opinion* 2008; 24(2): 469–80.

Yazici Y, **Shi N**, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: Analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. *Bulletin of the NYU Hospital for Joint Diseases* 2008; 66(2): 77–85.

Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. *HIV Medicine* 2007; 8(8): 483–90.

Ozminkowski RJ, Burton WN, **Goetzel RZ**, Maclean R, **Wang S**. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. *Journal of Occupational & Environmental Medicine* 2006; 48(2): 135–148.

Cardiovascular

Amin AN, **Lenhart G**, **Princic N**, Lin J, Thompson S, **Johnston S**. Retrospective administrative database study of the time period of venous thromboembolism risk during and following hospitalization for major orthopedic or abdominal surgery in real-world US patients. *Hospital Practice* 2011; 39(2): 7–17.

Deitelzweig SB, **Johnson BH**, Lin J, **Schulman KL**. Prevalence of clinical venous thromboembolism in the USA: Current trends and future projections. *American Journal of Hematology* 2011; 86(2): 217–20.



- Deitelzweig SB, Lin J, **Johnson BH, Schulman KL**. Venous thromboembolism in the US: Does race matter? *Journal of Thrombosis and Thrombolysis* 2011; 31(2): 133–8.
- Johnston SS, Curkendall S**, Makenbaeva D, Mozaffari E, **Goetzel R**, Burton W, Maclean R. The direct and indirect cost burden of acute coronary syndrome. *Journal of Occupational and Environmental Medicine* 2011; 53(1): 2–7.
- Kim MH, **Johnston SS, Chu BC**, Dalal MR, **Schulman KL**. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circulation Cardiovascular Quality and Outcomes* 2011; 4(3): 313–20.
- Amin AN, Lin J, **Johnson BH, Schulman KL**. Clinical and economic outcomes with appropriate or partial prophylaxis. *Thrombosis Research* 2010; 125(6): 513–7.
- Margolis J**, Gerber RA, Roberts C, Gheorghiadu M. Adherence to aldosterone-blocking agents in patients with heart failure. *American Journal of Therapeutics* 2010; 17(5): 446–54.
- Naccarelli GV, **Johnston SS**, Lin J, Patel PP, **Schulman KL**. Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. *Clinical Cardiology* 2010; 33(5): 270–9.
- Amin AN, Lin J, **Lenhart G, Schulman KL**. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. *Thrombosis and Haemostasis* 2009; 102(2): 321–6.
- Mark TL, Gibson TB**, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Managed Care* 2009; 15(2): 123–31.
- Naccarelli GV, **Varker H**, Lin J, **Schulman KL**. Increasing prevalence of atrial fibrillation and flutter in the United States. *American Journal of Cardiology* 2009; 104(11): 1534–9.
- Russell M, **Chu BC**, Banerjee A, Fan AZ, Trevisan M, Dorn JM, Gruenewald P. Drinking patterns and myocardial infarction: A linear dose-response model. *Alcoholism, Clinical and Experimental Research* 2009; 33(2): 324–31.
- Mark T**, Axelsen K, **Mucha L, Sadkova Y**. Racial differences in switching, augmentation and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. *The American Journal of Managed Care* 2007; 13 Suppl 3: S72–9.
- Nallamothu BK, **Young J**, Gurm HS, **Pickens G, Safavi K**. Recent trends in hospital utilization for acute myocardial infarction and coronary revascularization in the United States. *American Journal of Cardiology* 2007; 99(6): 749–53.
- Wang C, Kereiakes DJ, Bae JP, McCollam P, He J, **Griffin B**. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. *The Journal of Invasive Cardiology* 2007; 19(10): 431–6.
- Burleigh E, Wang C, **Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J**. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. *American Journal of Health System-Pharmacy* 2006; 63(20 Suppl 6): S23–9.



- Curkendall SM**, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada. *Annals of Epidemiology* 2006; 16(1): 63–70.
- Curkendall SM**, Lanes S, de Luise C, Stang MR, Jones JK, She D, Goehring E Jr. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. *European Journal of Epidemiology* 2006; 21(11): 803–13.
- Gibson TB, Mark TL**, Axelsen K, **Baser O**, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. *American Journal of Managed Care* 2006; 12(12 Spec No): SP11–9.
- Gibson TB, Mark TL**, McGuigan KA, Axelsen K, **Wang S**. The effects of prescription drug copayments on statin adherence. *American Journal of Managed Care* 2006; 12(9): 509–17.
- Huse DM, Song X, Ozminkowski RJ, Maguire J**, Williams SA, Borok GM, McDonough K. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. *Clinical Therapeutics* 2006; 28(9): 1425–42.
- Kohli M, Attard C, Lam A, **Huse D**, Cook J, Bourgault C, Alemao E, Yin D, Marentette M. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. *Pharmacoeconomics* 2006; 24: 815–830.
- Song X, Huse DM**, Williams SA, Borok GM, McDonough K, **Ozminkowski RJ**. A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs. *Journal of Occupational and Environmental Medicine* 2006; 48(10): 1014–22.
- Matson Koffman DM, **Goetzel RZ**, Anwuri VV, Shore KK, Orenstein D, LaPier T. Heart healthy and stroke free: successful business strategies to prevent cardiovascular disease. *American Journal of Preventative Medicine* 2005; 29(5 Suppl 1): 113–21.
- vanVonno CJ, **Ozminkowski RJ**, Smith MW, Thomas EG, Kelley D, **Goetzel R**, Berg GD, Jain SK, Walker DR. What can a pilot congestive heart failure disease management program tell us about likely return on investment? A case study from a program offered to federal employees. *Disease Management* 2005; 8(6): 346–360.
- Curkendall SM**, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. *Journal of Clinical Psychiatry* 2004; 65(5): 715–20.
- Wasserman J**, Whitmer RW, Bazzarre TL, **Kennedy ST, Merrick N, Goetzel RZ, Dunn RL, Ozminkowski RJ**, HERO Research Committee. Gender-specific effects of modifiable health risk factors on coronary heart disease and related expenditures. *Journal of Occupational and Environmental Medicine* 2000; 42(11): 1060–1069.
- Xuan J, Duong P, **Russo P**, Lacey MJ, Fu Q, Wong B. The economic burden of congestive heart failure in a managed care population. *The American Journal of Managed Care* 2000; 6(6): 693–700.



Depression

- Mark TL**, Joish VN, Hay JW, Sheehan DV, **Johnston SS**, **Cao Z**. Antidepressant use in geriatric populations: The burden of side effects and interactions and their impact on adherence and costs. *American Journal of Geriatric Psychiatry* 2011; 19(3): 211–21.
- Curkendall S**, **Ruiz KM**, Joish V, **Mark TL**. Productivity losses among treated depressed patients relative to healthy controls. *Journal of Occupational and Environmental Medicine* 2010; 52(2): 125–30.
- Gibson TB**, Jing Y, **Smith Carls G**, Kim E, **Bagalman JE**, Burton WN, Tran QV, Pikalov A, Goetzel RZ. Cost burden of treatment resistance in patients with depression. *American Journal of Managed Care* 2010; 16(5): 370–7.
- Mark TL**. For what diagnoses are psychotropic medications being prescribed? A nationally representative survey of physicians. *CNS Drugs* 2010; 24(4): 319–26.
- Henke RM**, Zaslavsky AM, McGuire TG, Ayanian JZ, Rubenstein LV. Clinical inertia in depression treatment. *Medical Care* 2009; 47(9): 959–67.
- Alegría M, Chatterji P, Wells K, **Cao Z**, Chen CN, Takeuchi D, Jackson J, Meng XL. Disparity in depression treatment among racial and ethnic minority populations in the United States. *Psychiatric Services* 2008; 59(11): 1264–72.
- Henke RM**, Chou AF, Chanin JC, Zides AB, Scholle SH. Physician attitude toward depression care interventions: Implications for implementation of quality improvement initiatives. *Implementation Science* 2008; 3: 40.
- Mark TL**. Receipt of psychotherapy by adolescents taking antidepressants. *Psychiatric Services* 2008; 59(9): 963.
- Larson MJ, **Miller K**, Fleming KJ. Treatment with antidepressant medications in private health plans. *Administration and Policy in Mental Health* 2007; 34(2): 116–26.
- Larson MJ, **Miller K**, Fleming KJ. Antidepressant medication use in private insurance health plans, 2002. *Psychiatric Services* 2006; 57(2): 175.
- Robinson RL, **Long SR**, **Chang S**, Able S, **Baser O**, Obenchain RL, Swindle RW. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. *Journal of Managed Care Pharmacy* 2006; 12(1): 43–54.
- Russell J, **Hawkins K**, **Ozminkowski R**, **Orsini L**, **Crown W**, **Kennedy S**, Finkelstein S, Berndt E, Rush J. Cost consequences of treatment-resistant depression. *Journal of Clinical Psychiatry* 2004; 65(3): 341–347.
- Crown W**, Finkelstein S, Berndt E, **Ling D**, **Poret A**, Rush J, Russell J. The impact of treatment-resistant depression on healthcare utilization and costs. *Journal of Clinical Psychiatry* 2002; 63(11): 963–971.



- Crystal-Peters J, Chang S, Long S, Tretiak R.** Health care expenditures of patients with major depressive disorder and post traumatic stress disorder. *European Psychiatry* 2002; 17 (1 Suppl.): 150.
- Goetzel RZ, Ozminkowski RJ, Sederer LI, Mark TL.** Working with depression, part I: The case for quality mental health services. *Business and Health* 2002; August 1.
- Goetzel RZ, Ozminkowski RJ, Sederer LI, Mark TL.** Working with depression, part II: Finding and funding effective treatment. *Business and Health* 2002; August 1.
- Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D.** Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. *International Journal of Clinical Practice* 2002; 56(6): 434–439.
- Crown W, Treglia M, Meneades L, White A.** Long-term costs of treatment for depression: Impact of drug selection and guideline adherence. *Value in Health* 2001; 4(4): 295–307.
- Crown W, Wan G, Berndt E, Finkelstein S, Ling D.** Differences in health care expenditures among patients treated for depression with or without anxiety. *Value in Health* 2001; 4(2): 148.
- Crown W.** Antidepressant selection and economic outcome: A review of methods and studies from clinical practice. *British Journal of Psychiatry* 2001; 179 (42 Suppl.): s18–s22.
- Poret AW, Neslusan C, Ricci JF, Wang S, Khan ZM, Kwong JW.** Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. *Value Health* 2001; 4(5): 362–369.
- Crown W.** Antidepressant use and clinical and economic outcomes in a primary care psychiatry center in Spain: A review of a naturalistic study. J. Guimón and N. Sartorius (eds) *Manage or Perish?* Kluwer Academic Publishers, 2000.
- Crown W.** Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. *Acta Psychiatrica Scandinavica* 2000; 101 (403 Suppl.): 62–66.

Diabetes and Metabolic

- Bonafede MM, Kalsekar A, Pawaskar M, Ruiz KM, Torres AM, Kelly KR, Curkendall SM.** Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: A retrospective database analysis. *BMC Endocrine Disorders* 2011; 11: 3.
- Carls GS, Gibson TB, Driver VR, Wrobel JS, Garoufalis MG, Defrancis RR, Wang S, Bagalman JE, Christina JR.** The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers. *Journal of the American Podiatric Medical Association* 2011; 101(2): 93–115.
- Francis BH, Song X, Andrews LM, Purkayastha D, Princic N, Sedgley R, Rudolph AE.** Progression to type 2 diabetes, healthcare utilization, and cost among pre-diabetic patients with or without comorbid hypertension. *Current Medical Research and Opinion* 2011; 27(4): 809–19.



- Johnston SS**, Conner C, Aagren M, **Smith DM**, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. *Diabetes Care* 2011; 34(5): 1164–70.
- Bonafede MM**, Kalsekar A, Pawaskar M, **Ruiz KM**, **Torres AM**, Kelly KR, **Curkendall SM**. A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures. *Patient Preference and Adherence* 2010; 4: 147–56.
- Gibson TB**, **Song X**, Alemayehu B, **Wang SS**, **Waddell JL**, Bouchard JR, Forma F. Cost sharing, adherence, and health outcomes in patients with diabetes. *American Journal of Managed Care* 2010; 16(8): 589–600.
- Goetzel RZ**, **Gibson TB**, **Short ME**, **Chu BC**, **Waddell J**, **Bowen J**, Lemon SC, Fernandez ID, Ozminkowski RJ, Wilson MG, DeJoy DM. A multi-worksites analysis of the relationships among body mass index, medical utilization, and worker productivity. *Journal of Occupational and Environmental Medicine* 2010; 52 Suppl 1: S52–8.
- Goetzel RZ**, Roemer EC, **Pei X**, **Short ME**, **Tabrizi MJ**, Wilson MG, DeJoy DM, Craun BA, Tully KJ, White JM, Baase CM. Second-year results of an obesity prevention program at the Dow Chemical Company. *Journal of Occupational and Environmental Medicine* 2010; 52(3): 291–302.
- Katz M, Scherger J, Conard S, **Montejano L**, **Chang S**. Healthcare costs associated with switching from brand to generic levothyroxine. *American Health & Drug Benefits* 2010; 3(2): 127–134.
- Lee LJ, **Anderson J**, Foster SA, Corrigan SM, **Smith DM**, **Curkendall S**. Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes. *Journal of Diabetes Science and Technology* 2010; 4(3): 547–557.
- Margolis J**, **Cao Z**, **Fowler R**, Harnett J, Sanchez RJ, Mardekian J, Silverman SL. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. *Journal of Medical Economics* 2010; 13(4): 738–47.
- Parker KB, DeJoy DM, Wilson MG, Bowen HM, **Goetzel RZ**. Application of the Environmental Assessment Tool (EAT) as a process measure for a worksite weight management intervention. *Journal of Occupational and Environmental Medicine* 2010; 52 Suppl 1: S42–51.
- Curkendall SM**, Natoli JL, Alexander CM, Nathanson BH, Haidar T, Dubois RW. Economic and clinical impact of inpatient diabetic hypoglycemia. *Endocrine Practice* 2009; 15(4): 302–12.
- Durden ED**, Alemayehu B, Bouchard JR, **Chu BC**, Aagren M. Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. *Journal of Occupational and Environmental Medicine* 2009; 51(12): 1460–5.
- Goetzel RZ**, **Baker KM**, **Short ME**, **Pei X**, **Ozminkowski RJ**, **Wang S**, **Bowen JD**, Roemer EC, Craun BA, Tully KJ, Baase CM, DeJoy DM, Wilson MG. First-year results of an obesity prevention program at the Dow Chemical Company. *Journal of Occupational and Environmental Medicine* 2009; 51(2): 125–138.
- Alexander CM, **Landsman PB**, Grundy SM. The influence of age and body mass index on the metabolic syndrome and its components. *Diabetes, Obesity & Metabolism* 2008; 10(3): 246–50.



- Baker KM, Goetzel RZ, Pei X, Weiss AJ, Bowen J, Tabrizi MJ, Nelson CF, Metz RD, Pelletier KR, Thompson E.** Using a return-on-investment estimation model to evaluate outcomes from an obesity management worksite health promotion program. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 981–990.
- Durden ED, Huse D, Ben-Joseph R, Chu BC.** Economic costs of obesity to self-insured employers. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 991–7.
- Orzeck EA, **Shi N**, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. *Clinical Therapeutics* 2007; 29(10): 2246–55.
- Pratt CA, Lemon SC, Fernandez ID, **Goetzel R**, Beresford SA, French SA, Stevens VJ, Vogt TM, Webber LS. Design characteristics of worksite environmental interventions for obesity prevention. *Obesity* 2007; 15(9): 2171–80.
- Wilson MG, **Goetzel RZ, Ozminkowski RJ, DeJoy DM, Della L, Roemer EC, Schneider J, Tully KJ, White JM, Baase CM.** Using formative research to develop environmental and ecological interventions to address overweight and obesity. *Obesity* 2007; 15(Suppl 1): 37S–47S.
- Rhoads GG, **Orsini LS, Crown W, Wang S, Getahun D, Zhang Q.** Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. *Journal of Occupational and Environmental Medicine* 2005; 47(5): 447–452.
- Cohen FJ, **Neslusan CA, Conklin JE, Song X.** Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. *Diabetes Care* 2003; 26(6): 1847–1851.
- Wasserman J, Boyce-Smith G, Hopkins DS, Schabert V, Davidson MB, Ozminkowski RJ, Albright A, Kennedy S.** A comparison of diabetes patients' self-reported health status with hemoglobin A1c test results in 11 California health plans. *Managed Care* 2001; 10(3): 58–70.
- Ozminkowski R, Wang S, Marder WD, Azzolini J.** Short-run associations between medical care expenditures and adherence to clinical practice guideline-based measures for diabetes. *Value in Health* 2000; 3(s1): 29–38.

Drug Spending

- Mucha L, Masia NA, Axelsen KJ.** Per-patient-per-month drug costs in Medicare Part D protected classes. *Pharmacoeconomics* 2006; 24 Suppl 3: 79–84.
- Gibson TB, McLaughlin CG, Smith DG.** A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures. *Inquiry* 2005; 42: 293–310.
- Gibson TB, Ozminkowski RJ, Goetzel RZ.** The effects of prescription drug cost sharing: A review of the evidence. *The American Journal of Managed Care* 2005; 11: 730–740.
- Mark TL, Ozminkowski RJ.** What will be the impact of the medicare doughnut hole? *Drug Benefit Trends* 2005; June: 254–260.



- Goetzel RZ, Ozminkowski RJ, Schutt DC.** The value of pharmaceuticals—Some direction for employers. *Employee Benefits Journal* 2002; 27(3): 31–35.
- Chawla AJ, Hatzmann MH, Long SR.** Developing performance measures for prescription drug management. *Health Care Financing Review* 2001; 22(3): 71–84.
- Gibson TB, McLaughlin CG, Smith DG.** Cost-sharing for prescription drugs. *The Journal of the American Medical Association* 2001; 285(18): 2328–9.
- Dubois RW, **Chawla AJ, Neslusan CA, Smith MW,** Wade S. Explaining drug spending trends: Does perception match reality? *Health Affairs* 2000; 19(2): 231–239.

Health and Productivity Management

- Carls GS, Goetzel RZ, Henke RM,** Bruno J, Isaac F, McHugh J. The impact of weight gain or loss on healthcare costs for employees at the Johnson & Johnson family of companies. *Journal of Occupational and Environmental Medicine* 2011; 53(1): 8–16.
- Della LJ, DeJoy DM, Mitchell SG, **Goetzel RZ,** Roemer EC, Wilson MG. Management support of workplace health promotion: Field test of the leading by example tool. *American Journal of Health Promotion* 2010; 25(2): 138–46.
- Goetzel RZ,** Pronk NP. Worksite health promotion: How much do we really know about what works? *American Journal of Preventative Medicine* 2010; 38(2 Suppl): S223–5.
- Henke RM, Carls GS, Short ME, Pei X, Wang S,** Moley S, Sullivan M, **Goetzel RZ.** The relationship between health risks and health and productivity costs among employees at Pepsi Bottling Group. *Journal of Occupational and Environmental Medicine* 2010; 52(5): 519–27.
- Kelly E, Carls GS, Lenhart G,** Mauceri E, Columbus D, Cavuoti A, **Goetzel RZ.** The Novartis health index: A method for valuing the economic impact of risk reduction in a workforce. *Journal of Occupational and Environmental Medicine* 2010; 52(5): 528–35.
- Kowlessar NM, **Henke RM, Goetzel RZ,** Colombi AM, Felter EM. The influence of worksite health promotion program management and implementation structure variables on medical care costs at PPG Industries. *Journal of Occupational and Environmental Medicine* 2010; 52(12): 1160–6.
- Rousculp MD, **Johnston SS, Palmer LA, Chu BC,** Mahadevia PJ, Nichol KL. Attending work while sick: Implication of flexible sick leave policies. *Journal of Occupational and Environmental Medicine* 2010; 52(10): 1009–13.
- Short ME, Goetzel RZ, Young JS, Kowlessar NM,** Liss-Levinson RC, **Tabrizi MJ,** Roemer EC, **Sabatelli AA,** Winick K, Montes M, Crighton KA. Measuring changes in lipids and blood glucose values in health and wellness program of Prudential Financial, Inc. *Journal of Occupational and Environmental Medicine* 2010; 52(8): 797–806.



- Soler RE, Leeks KD, Razi S, Hopkins DP, Griffith M, Aten A, Chattopadhyay SK, Smith SC, Habarta N, **Goetzel RZ**, Pronk NP, Richling DE, Bauer DR, Buchanan LR, Florence CS, Koonin L, MacLean D, Rosenthal A, Matson Koffman D, Grizzell JV, Walker AM; Task Force on Community Preventive Services. A systematic review of selected interventions for worksite health promotion. The assessment of health risks with feedback. *American Journal of Preventative Medicine* 2010; 38(2 Suppl): S237–62.
- Bowen JD, Goetzel RZ, Lenhart G, Ozminkowski RJ**, Babamoto KS, Portale JD. Using a personal health care cost calculator to estimate future expenditures based on individual health risks. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 449–55.
- Goetzel RZ**. Do prevention or treatment services save money? The wrong debate. *Health Affairs* 2009; 28(1): 37–41.
- Goetzel RZ, Carls GS, Wang S, Kelly E**, Mauceri E, Columbus D, Cavuoti A. The relationship between modifiable health risk factors and medical expenditures, absenteeism, short-term disability, and presenteeism among employees at Novartis. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 487–99.
- Goetzel RZ**, Liss-Levinson RC, Goodman N, Kennedy JX. Development of a community-wide cardiovascular risk reduction assessment tool for small rural employers in upstate New York. *Preventing Chronic Disease* 2009; 6(2): A65.
- Goetzel RZ**, Roemer EC, **Short ME, Pei X, Tabrizi MJ**, Liss-Levinson RC, Samoly DK, Luisi D, Quitoni K, Dumanovsky T, Silver LD, **Ozminkowski RJ**. Health improvement from a worksite health promotion private-public partnership. *Journal of Occupational and Environmental Medicine* 2009; 51(3): 296–304.
- Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB**, DeJoy DM, Wilson MG. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. *Journal of Occupational and Environmental Medication* 2009; 51(7): 786–96.
- Della LJ, DeJoy DM, **Goetzel RZ, Ozminkowski RJ**, Wilson MG. Assessing management support for worksite health promotion: psychometric analysis of the leading by example (LBE) instrument. *American Journal of Health Promotion* 2008; 22(5): 359–67.
- DeJoy DM, Wilson MG, **Goetzel RZ, Ozminkowski RJ, Wang S**, Baker KM, Bowen HM, Tully KJ. Development of the Environmental Assessment Tool (EAT) to measure organizational physical and social support for worksite obesity prevention programs. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 126–137.
- Goetzel RZ**, Luisi D, **Ozminkowski RJ**, Roemer EC, Taher S. Baseline characteristics of workers at ten New York City employers recruited for a private-public research collaborative. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 190–201.
- Goetzel RZ, Ozminkowski RJ**. The health and cost benefits of work site health-promotion programs. *Annual Review of Public Health* 2008; 29: 303–23.



- Goetzel RZ, Ozminkowski RJ, Bowen J, Tabrizi MJ,** Weiss A, Hohlbauch A, DeJoy DM, Wilson M, Roemer EC, Mummert A, **Baker K, Short M,** Liss-Levinson R, Samoly D. Employer integration of health promotion and health protection programs. *International Journal of Workplace Health Management* 2008; 1(2): 109–122.
- Mitchell SG, Goetzel RZ, Ozminkowski RJ.** The value of worksite health promotion. *ACSM's Health & Fitness Journal* 2008; 12(2): 23–27.
- Naydeck BL, Pearson JA, **Ozminkowski RJ,** Day BT, **Goetzel RZ.** The impact of the Highmark employee wellness programs on 4-year healthcare costs. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 146–156.
- Goetzel RZ, Ozminkowski RJ,** Pelletier KR, Metz RD, Chapman LS. Emerging trends in health and productivity management. *American Journal of Health Promotion* 2007; 22(1): Suppl 1–7, iii.
- Goetzel RZ,** Reynolds K, Breslow L, Roper WL, **Shechter D,** Stapleton DC, Lapin PJ, McGinnis JM. Health promotion in later life: It's never too late. *American Journal of Health Promotion* 2007; 21(4): 1–5, iii.
- Goetzel RZ, Shechter D, Ozminkowski RJ,** Marmet PF, **Tabrizi MJ,** Roemer EC. Promising practices in employer health and productivity management efforts: Findings from a benchmarking study. *Journal of Occupational and Environmental Medicine* 2007; 49(2): 111–130.
- Goetzel RZ, Shechter D, Ozminkowski RJ,** Stapleton DC, Lapin PJ, McGinnis JM, Gordon CR, Breslow L. Can health promotion programs save Medicare money? *Clinical Interventions in Aging* 2007; 2(1): 117–122.
- Goetzel R, Ozminkowski R.** Integrating to improve productivity. *Journal of Employee Assistance* 2006; 36(4): 25–28.
- Goetzel RZ, Ozminkowski RJ.** What's holding you back: Why should (or shouldn't) employers invest in health promotion programs for their workers? *North Carolina Medical Journal* 2006; 67(6): 428–30.
- Ozminkowski RJ, Goetzel RZ,** Wang F, **Gibson TB, Shechter D,** Musich S, Bender J, Edington DW. The savings gained from participation in health promotion programs for Medicare beneficiaries. *Journal of Occupational and Environmental Medicine* 2006; 48(11): 1125–1132.
- Collins JJ, Baase CM, Sharda CE, **Ozminkowski RJ,** Nicholson S, Billotti GM, Turpin RS, Olson M, Berger ML. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. *Journal of Occupational and Environmental Medicine* 2005; 47(6): 547–557.
- Goetzel RZ.** Better outcomes through health and productivity management. *Managed Care* 2005; 14(10 Suppl): 28–36.
- Goetzel RZ, Ozminkowski RJ,** Baase CM, Billotti GM. Estimating the return-on-investment from changes in employee health risks on the Dow Chemical Company's health care costs. *Journal of Occupational and Environmental Medicine* 2005; 47(8): 759–768.



- Goetzel RZ, Ozminkowski RJ, Villagra VG, Duffy J.** Return on investment in disease management: A review. *Health Care Financing Review* 2005; 26(4): 1–19.
- Lynch WD, Chikamoto Y, Imai K, Lin TF, Kenkel DS, **Ozminkowski RJ, Goetzel RZ.** The association between health risks and medical expenditures in a Japanese corporation. *American Journal of Health Promotion* 2005; 19(3 Suppl.): 238–248.
- Nicholson S, Pauly MV, Polsky D, Baase CM, Billotti GM, **Ozminkowski RJ, Berger ML, Sharda CE.** How to present the business case for healthcare quality to employers. *Applied Health Economics and Health Policy* 2005; 4(4): 209–218.
- Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W.** Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. *Journal of Occupational and Environmental Medicine* 2004; 46(4): 398–412.
- Ozminkowski RJ, Goetzel RZ, Chang S, Long S.** The application of two health and productivity instruments at a large employer. *Journal of Occupational and Environmental Medicine* 2004; 46(7): 635–648.
- Ozminkowski RJ, Goetzel RZ, Santoro J, Saenz BJ, Eley C, Gorsky B.** Estimating risk reduction required to break even in a health promotion program. *American Journal of Health Promotion* 2004; 18(4): 316–325.
- Turpin RS, **Ozminkowski RJ, Sharda CE, Collins JJ, Berger ML, Billotti GM, Baase CM, Olson MJ, Nicholson S.** Reliability and validity of the Stanford Presenteeism Scale. *Journal of Occupational and Environmental Medicine* 2004; 46(11): 1123–1133.
- Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S.** The health and productivity cost burden of the ‘top 10’ physical and mental health conditions affecting six large U.S. employers in 1999. *Journal of Occupational and Environmental Medicine* 2003; 45(1): 5–14.
- Goetzel RZ, Ozminkowski RJ, Long SR.** Development and reliability analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *Journal of Occupational and Environmental Medicine* 2003; 45(7): 743–762.
- Ozminkowski RJ, Goetzel RZ, Long SR.** A validity analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *Journal of Occupational and Environmental Medicine* 2003; 45(11): 1183–1195.
- Ozminkowski RJ, Mark TL, Goetzel RZ, Blank D, Walsh JM, Cangianelli L.** Relationships between urinalysis testing for substance use, medical expenditures, and the occurrence of injuries at a large manufacturing firm. *The American Journal of Drug and Alcohol Abuse* 2003; 29(1): 151–167.
- Goetzel RZ, Ozminkowski RJ, Bruno JA, Rutter KR, Isaac F, Wang S.** The long term impact of Johnson & Johnson’s Health & Wellness program on employee health risks. *Journal of Occupational and Environmental Medicine* 2002; 44(5): 417–424.
- Goetzel RZ, Ozminkowski RJ, Sederer LI, Mark TL.** The business case for quality mental health services: Why employers should care about the health and well-being of their employees. *Journal of Occupational and Environmental Medicine* 2002; 44(4): 320–330.



- Goetzel RZ, Ozminkowski RJ, Yuhasz L.** Health and productivity management: What does this have to do with health promotion? Adapted by Wolf Kirstein, *Health Promotion Global Perspectives* 2002; 4(2): 2–3.
- Goetzel RZ, Ozminkowski RJ.** Program evaluation. Chapter 5, *Health Promotion in the Workplace*, Third Edition, Michael P. O'Donnell (ed.), Albany, NY: Delmar/Thomson Learning, 2002.
- Ozminkowski RJ, Ling D, Goetzel RZ,** Bruno JA, Rutter KR, Isaac F, **Wang S.** Long-term impact of Johnson & Johnson's Health & Wellness program on health care utilization and expenditures. *Journal of Occupational and Environmental Medicine* 2002; 44(1): 21–29.
- Goetzel RZ, Guindon AM,** Turshen IJ, **Ozminkowski RJ.** Health and productivity management: Establishing key performance measures, benchmarks, and best practices. *Journal of Occupational and Environmental Medicine* 2001; 43(1):10–17.
- Goetzel RZ, Ozminkowski RJ, Ascuitto AJ, Chouinard P, Barrett M.** Survey of Koop Award winners: Life-cycle insights. *The Art of Health Promotion* 2001; 5(2).
- Goetzel RZ, Ozminkowski RJ, Schutt DC.** Pharmaceuticals—cost or investment? Chapter 36 in *Employee Benefit Issues: The Multiemployer Perspective*. Volume 43 (2001), Brookfield, WI: International Foundation of Employee Benefit Plans.
- Goetzel RZ.** A corporate perspective: Reflections from the economic buyer of health promotion programs (introduction to the Corporate Perspectives section of special issue). *American Journal of Health Promotion* 2001; 15(5): 357.
- Goetzel RZ.** The financial impact of health promotion and disease prevention programs—Why is it so hard to prove value? (introduction to special issue). *American Journal of Health Promotion* 2001; 15(5): 277–80.
- Ozminkowski RJ, Goetzel RZ, Crown WH.** Productivity measurement for pharmacoeconomic and outcomes research studies. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) News* 2001; December 15.
- Ozminkowski RJ, Goetzel RZ.** Getting closer to the truth: Overcoming research challenges when estimating the financial impact of worksite health promotion programs. *American Journal of Health Promotion* 2001; 15(5): 289–295.
- Anderson DR, Whitmer RW, **Goetzel RZ, Ozminkowski RJ,** Dunn RL, Wasserman J, Serxner S; Health Enhancement Research Organization (HERO) Research Committee. The relationship between modifiable health risks and group-level health care expenditures. *American Journal of Health Promotion* 2000; 15(1): 45–52.
- Crown W.** Productivity measurement in pharmaceutical studies. *Drug Benefit Trends* 2000; 12(2): 5–8.
- Goetzel RZ, Ozminkowski RJ.** Disease management as a part of total health and productivity management. *Disease Management & Health Outcomes* 2000; 8(3): 121–128.
- Goetzel RZ, Ozminkowski RJ.** Health and productivity management: Emerging opportunities for health promotion professionals for the 21st century. *American Journal of Health Promotion* 2000; 14(4): 211–214.



Goetzel RZ, Ozminkowski RJ, Del Rosso G, Schutt DC. Are drugs a cost or an investment? *Business & Health* 2000; June: 39–45.

Goetzel RZ, Ozminkowski RJ, Meneades L, Stewart M, Schutt DC. Pharmaceuticals—Cost or investment? An employer's perspective. *Journal of Occupational and Environmental Medicine* 2000; 42(4): 338–351.

Leutzinger JA, **Ozminkowski RJ**, Dunn RL, **Goetzel RZ**, Richling DE, Stewart M, Whitmer RW. Projecting future medical care costs using four scenarios of lifestyle risk rates. *American Journal of Health Promotion* 2000; 15(1): 35–44.

Ozminkowski RJ, Goetzel RZ, Smith MW, Cantor RI, Shaughnessy A, Harrison M. The impact of the Citibank, N.A., health management program on changes in employee health risks over time. *Journal of Occupational and Environmental Medicine* 2000; 42(5): 502–511.

Infectious Diseases

Palmer L, Hall CB, Katkin JP, **Shi N**, Masaquel AS, McLaurin KK, Mahadevia PJ. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. *Current Medical Research and Opinion* 2011; 27(2): 403–12.

Shi N, Palmer L, Chu BC, Katkin JP, Hall CB, Masaquel AS, Mahadevia PJ. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: A Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. *Journal of Medical Economics* 2011; 14(3): 335–40.

Curns AT, Steiner CA, Barrett M, **Hunter K, Wilson E**, Parashar UD. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: Analysis of hospital discharge data from 18 US states. *Journal of Infectious Diseases* 2010; 201(11): 1617–24.

Johnston SS, Rousculp MD, **Palmer LA, Chu BC**, Mahadevia PJ, Nichol KL. Employees' willingness to pay to prevent influenza. *American Journal of Managed Care* 2010; 16(8): e205–14.

Palmer L, Hall CB, Katkin JP, **Shi N**, Masaquel AS, McLaurin KK, Mahadevia PJ. Healthcare costs within a year of respiratory syncytial virus among medicaid infants. *Pediatric Pulmonology* 2010; 45(8): 772–81.

Palmer LA, Rousculp MD, **Johnston SS**, Mahadevia PJ, Nichol KL. Effect of influenza-like illness and other wintertime respiratory illnesses on worker productivity: The child and household influenza-illness and employee function (CHIEF) study. *Vaccine* 2010; 28(31): 5049–5056.

Landsman PB, Smith DG, Fendrick AM. Healthcare utilization in community-acquired pneumonia episodes of care: A comparison across the continuum of managed care. *Medical Care* 2009; 47(10): 1084–90.

Madjid M, **Curkendall S**, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. *Cardiology* 2009; 113(2): 98–107.



- Piedra PA, **Schulman KL**, Blumentals WA. Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. *Pediatrics* 2009; 124(1): 170–8.
- Peters PH, Moscona A, **Schulman KL**, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. *Medscape Journal of Medicine* 2008; 10(6): 131.
- Barr C, **Schulman K**, Iacuzio D, Bradley J. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. *Current Medical Research and Opinion* 2007; 23(3): 523–31.
- Blumentals WA, **Schulman KL**. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: Results from a retrospective population-based study. *Current Medical Research and Opinion* 2007; 23(12):2961–70.
- Blumentals WA, **Song X**. The safety of oseltamivir in patients with influenza: Analysis of healthcare claims data from six influenza seasons. *Medscape General Medicine* 2007; 9(4): 27–32.
- Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, **Young JK**, Cooper LM. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: A database cohort study of hospital mortality, length of stay, and costs. *Current Medical Research and Opinion* 2007; 23(1): 235–44.
- Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J**. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. *Disease Management* 2002; 5(2): 95–107.
- Siddique R, **Neslusan CA, Crown WH, Crystal-Peters J**, Sloan S, Farup C. A national inpatient cost estimate of percutaneous endoscopic gastrostomy (PEG)-associated aspiration pneumonia. *The American Journal of Managed Care* 2000; 6(4): 490–496.

Men's Health

- McVary K, **Foley KA, Long SR**, Sander S, Curtice TG, Shah H. Identifying patients with benign prostatic hyperplasia through a diagnosis of, or treatment for, erectile dysfunction. *Current Medical Research and Opinion* 2008; 24(3): 775–84.
- Thomas P, **Goetzel RZ, Ozminkowski RJ**, Kassabian VS, **Schutt DC**. Results of a men's urological health screening program at Lockheed Martin Aeronautical Systems. *Disease Management Health Outcomes* 2003; 11(3): 181–189.
- Thomas P, **Goetzel RZ, Ozminkowski RJ**, Kassabian VS, **Schutt DC**. If men won't go to doctors... *Business and Health* 2002; June 19.



Mental Health

Mark TL, Levit KR, Vandivort-Warren R, Buck JA, Coffey RM. Changes In US spending on mental health and substance abuse treatment, 1986–2005, and implications for policy. *Health Affairs* 2011; 30(2): 284–92.

Gibson TB, Jing Y, Kim E, Bagalman E, Wang S, Whitehead R, Tran QV, Doshi JA. Cost-sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. *Managed Care* 2010; 19(8): 40–7.

Mark TL, Gibson TB, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Psychiatry* 2010; 167(10): 1202–9.

Mark TL, Vandivort-Warren R, Owens PL, Buck JA, Levit KR, Coffey RM, Stocks C. Psychiatric discharges in community hospitals with and without psychiatric units: How many and for whom? *Psychiatric Services* 2010; 61(6): 562–8.

Mark TL, Levit KR, Buck JA. Datapoints: Psychotropic drug prescriptions by medical specialty. *Psychiatric Services* 2009; 60(9): 1167.

Rothbard AB, **Miller K, Lee S, Blank M.** Revised cost estimates of Medicaid recipients with serious mental illness and HIV-AIDS. *Psychiatric Services* 2009; 60(7): 974–7.

Coffey RM, Buck JA, Kassed CA, Dilonardo J, Forhan C, Marder WD, Vandivort-Warren R. Transforming mental health and substance abuse data systems in the United States. *Psychiatric Services* 2008; 59(11): 1257–63.

Dilonardo J, **Coffey R, Vandivort-Warren R, Buck J.** Inpatient utilization for persons with co-occurring disorders. *Psychiatric Services* 2008; 59(1): 14.

Levit KR, Kassed CA, Coffey RM, Mark TL, Stranges EM, Buck JA, Vandivort-Warren R. Future funding for mental health and substance abuse: Increasing burdens for the public sector. *Health Affairs* 2008; 27(6): w513–22.

Mark TL, Harwood HJ, McKusick DC, King EC, Vandivort-Warren R, Buck JA. Mental health and substance abuse spending by age, 2003. *Journal of Behavioral Health Services and Research* 2008; 35(3): 279–89.

Larson MJ, **Miller K, Fleming KJ, Teich JL.** Mental health services for children in large, employer-based health plans, 1999. *The Journal of Behavioral Health Services & Research* 2007; 34(1): 56–72.

Mark TL, Levit KR, Coffey RM, Buck JA, Vandivort-Warren R. Mental health treatment expenditure trends, 1986–2003. *Psychiatric Services* 2007; 58(8):1041–8.

Thomas CP, Hodgkin D, Wallack SS, Martin T, Ritter GA, **Mark TL.** Mental health and substance abuse treatment prescription drugs: Lessons from a period of high spending growth. *Journal of Pharmaceutical Finance, Economics & Policy* 2007; 16(3): 67–83.



- Buck JA, **Mark TL**. Datapoints: State-administered spending on mental health services by type of service. *Psychiatric Services* 2006; 57(1): 29.
- Mark TL**, Buck J. Characteristics of U.S. youths with serious emotional disturbance: Data from the national health interview survey. *Psychiatric Services* 2006; 57(11): 1573–8.
- Bray JW, Davis KL, Graver L, **Schroeder D**, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. *Journal of Behavioral Health Services & Research* 2005; 32(3): 282–93.
- Mark TL**, Buck JA. Components of spending for Medicaid mental health services, 2001. *Psychiatric Services* 2005; 56(6): 648.
- Mark TL**, **Coffey RM**, Vandivort-Warren R, Harwood HJ, King EC, MHSA Spending Estimates Team. U.S. spending for mental health and substance abuse treatment, 1991–2001. *Health Affairs* 2005; Jan–Jun Suppl Web Exclusives: W5–133–W5–142.
- Finkelstein E, Bray J, Larson MJ, **Miller K**, Tompkins C, Keme A, Manderscheid R. Prevalence of, and payments for, mental health and substance abuse disorders in public and private health plans. SAMHSA/CMHS (Center for Mental Health Services) Mental Health, United States 2002, 165–185, 2004.
- Harwood HJ, **Mark TL**, McKusick DR, **Coffey RM**, King EC, Genuardi JS. National spending on mental health and substance abuse treatment by age of clients, 1997. *The Journal of Behavioral Health Services & Research* 2003; 30(4): 433–43.
- Mark TL**, Buck JA, Dilonardo JD, **Coffey RM**, Chalk M. Medicaid expenditures on behavioral health care. *Psychiatric Services* 2003; 54(2): 188–194.
- Mark TL**, **Palmer LA**, **Russo PA**, Vasey J. Examination of treatment pattern differences by race. *Mental Health Services Research* 2003; 5(4): 241–250.
- Teich J, **Buck J**, **Graver L**, **Schroeder D**, **Zheng D**. Utilization of public mental health services by children with serious emotional disturbances. *Administration and Policy in Mental Health* 2003; 30(6): 523–34.
- McKusick DR, **Mark TL**, King EC, **Coffey RM**, Genuardi J. Trends in mental health insurance benefits and out-of-pocket spending. *The Journal of Mental Health Policy and Economics* 2002; 5(2): 21–31.
- McCulloch JM, **Ozminkowski RJ**, Cuffel B, Dunn RL, Goldman W, Kelleher D, **Comporato A**. Analysis of a managed psychiatric disability program. *Journal of Occupational and Environmental Medicine* 2001; 43(2): 101–109.
- Ettner SL, Frank RG, **Mark TL**, **Smith MW**. Risk adjustment of capitation payments to behavioral health care carve-outs: How well do existing methodologies account for psychiatric disability? *Health Care Management Science* 2000; 3(2): 159–169.
- Mark TL**, **Coffey RM**, King E, Harwood H, McKusick D, Genuarid J, Dilonardo J, Buck J. Spending on mental health and substance abuse treatment, 1987–1997. *Health Affairs* 2000; 19(4): 108–120.



Shea D, **Russo P**, Smyer M. Use of mental health services by persons with a mental illness in nursing facilities: Initial impacts of OBRA87. *Journal of Aging and Health* 2000; 12(4): 560–577.

Neurology and Pain

Harnett J, **Margolis J**, **Cao Z**, **Fowler R**, Sanchez RJ, Mardekian J, Silverman SL. Real-world evaluation of healthcare resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine. *Pain Practice* 2011; 11(3): 217–29.

Margolis JM, **Cao Z**, Onukwugha E, Sanchez RJ, Alvir J, Joshi AV, Mullins CD. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. *American Journal of Managed Care* 2010; 16(6): 447–56.

Sarsour K, Morin CM, **Foley K**, Kalsekar A, Walsh JK. Association of insomnia severity and comorbid medical and psychiatric disorders in a health plan-based sample: Insomnia severity and comorbidities. *Sleep Medicine* 2010; 11(1): 69–74.

Margolis JM, **Johnston SS**, **Chu BC**, Onukwugha E, Hvidsten K, Alvir J, Rossi JG, Mullins CD. Effects of a Medicaid prior authorization policy for pregabalin. *American Journal of Managed Care* 2009; 15(10): e95–e102.

Silverman S, Dukes EM, **Johnston SS**, Brandenburg NA, Sadosky A, **Huse DM**. The economic burden of fibromyalgia: Comparative analysis with rheumatoid arthritis. *Current Medical Research and Opinion* 2009; Feb 17; 25(4): 829–40.

Hawkins K, **Wang S**, Rupnow M. Direct cost burden among insured US employees with migraine. *Headache* 2008; 48(4): 553–63.

Mucha L, **Wang S**, Cuffel B, McRae T, **Mark TL**, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. *Journal of Managed Care Pharmacy* 2008; 14(5): 451–61.

Botteman MF, **Ozminkowski RJ**, **Wang S**, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: A decision analytical model. *CNS Drugs* 2007; 21(4): 319–334.

Chu BC, Millis S, Arango-Lasprilla JC, Hanks R, Novack T, Hart T. Measuring recovery in new learning and memory following traumatic brain injury: A mixed-effects modeling approach. *Journal of Clinical and Experimental Neuropsychology* 2007; 29(6): 617–25.

Hawkins K, **Wang S**, Rupnow MF. Indirect cost burden of migraine in the United States. *Journal of Occupational and Environmental Medicine* 2007; 49(4): 368–374.

Hutchings A, Calloway M, Choy E, Hooper M, Hunter DJ, Jordan JM, Zhang Y, **Baser O**, **Long S**, **Palmer L**. The Longitudinal Examination of Arthritis Pain (LEAP) study: Relationships between weekly fluctuations in patient-rated joint pain and other health outcomes. *The Journal of Rheumatology* 2007; 34(11): 2291–300.



Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in the United States. *Sleep* 2007; 30(3): 263–73.

Huse DM, Castelli-Haley J, **Orsini LS, Lenhart G**, Abdalla JA. Patterns of initial pharmacotherapy for Parkinson's disease in the United States. *Journal of Geriatric Psychiatry and Neurology* 2006; 19(2): 91–97.

Finkel S, Kozma C, **Long S**, Greenspan A, Mahmoud R, **Baser O**, Engelhart L. Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. *International Psychogeriatrics* 2005; 17(4): 1–13.

Huse DM, Schulman K, Orsini L, Castelli-Haley J, **Kennedy S, Lenhart G**. Burden of illness in Parkinson's disease. *Movement Disorders* 2005; 20(11): 1449–1454.

Ozminkowski RJ, Marder WD, Hawkins K, Wang S, Stallings SC, Finkelstein SN, Sinskey AJ, Wierz D. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. *Clinical Therapeutics* 2004; 26(8): 1341–1354.

Stang PE, **Crown WH, Bizier R**, Chatterton ML, White R. The family impact and costs of migraine. *American Journal of Managed Care* 2004; 10(5): 313–320. (Kenneth M. Langa, MD, wrote an editorial about this article that was titled “An Illness in the Family: Accounting for the Complex Effects of Illness on Other Family Members” and was published in the same issue of *JOEM*.)

Oncology

Song X, Varker H, Eichelbaum M, Stopfer P, Shahidi M, **Wilson K**, Kaiser R, Finnern HW. Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes. *Lung Cancer* 2011; March 5; [Epub ahead of print].

Song X, Zhao Z, Barber B, **Gregory C, Cao Z**, Gao S. Cost of illness in patients with metastatic colorectal cancer. *Journal of Medical Economics* 2011; 14(1): 1–9.

Song X, Zhao Z, Barber B, **Gregory C**, Wang PF, **Long SR**. Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. *Current Medical Research and Opinion* 2011; 27(1): 123–30.

Barlev A, **Song X, Ivanov B**, Setty V, Chung K. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. *Journal of Managed Care Pharmacy* 2010; 16(9): 693–702.

Chu E, **Schulman KL**, McKenna EF Jr, Cartwright T. Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: A cost comparison. *Clinical Colorectal Cancer* 2010; 9(4): 229–37.

Foley KA, Wang PF, Barber BL, **Long SR, Bagalman JE**, Wagner V, **Song X**, Zhao Z. Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. *Annals of Oncology* 2010; 21(7): 1455–61.



- Meadows ES, **Johnston SS**, **Cao Z**, **Foley KA**, Pohl GM, Johnston JA, Ramsey SD. Illness-associated productivity costs among women with employer-sponsored insurance and newly diagnosed breast cancer. *Journal of Occupational and Environmental Medicine* 2010; 52(4): 415–20.
- Rugo HS, Kohles J, **Schulman KL**. Cost comparison of capecitabine in patients with breast cancer. *American Journal of Clinical Oncology* 2010; 33(6): 550–6.
- Chu E, **Schulman KL**, Zelt S, **Song X**. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. *Cancer* 2009; 115(7): 1412–23.
- Chu E, **Shi N**, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. *Oncology* 2009; 77(3–4): 244–53.
- Lee DW, Stang PE, Goldberg GA, **Haberman M**. Resource use and cost of diagnostic workup of women with suspected breast cancer. *The Breast Journal* 2009; 15(1): 85–92.
- Madeb R, Golijanin D, Noyes K, Fisher S, **Stephenson JJ**, **Long SR**, Knopf J, Lyman GH, Messing EM. Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. *Cancer* 2009; 115(12): 2660–70.
- Saif MW, **Shi N**, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. *World Journal of Gastroenterology* 2009; 15(35): 4415–22.
- Mark TL**, Fortner B, Johnson G. Evaluation of a tablet PC technology to screen and educate oncology patients. *Supportive Care in Cancer* 2008; 16(4): 371–8.
- Mark TL**, Johnson G, Fortner B, **Ryan K**. The benefits and challenges of using computer-assisted symptom assessments in oncology clinics: Results of a qualitative assessment. *Technology in Cancer Research & Treatment* 2008; 7(5): 401–6.
- Huse DM**, von Mehren M, **Lenhart G**, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors. *Clinical Drug Investigation* 2007; 27(2): 85–93.
- Krupski TL, **Foley KA**, **Baser O**, **Long S**, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy, and bone complications. *The Journal of Urology* 2007; 178(4 Pt 1): 1423–8.
- Kutikova L, Bowman L, **Chang S**, **Long SR**, Thornton DE, **Crown WH**. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. *Journal of Neurooncology* 2007; 81(1): 61–5.
- Mortimer JE, **Schulman K**, Kohles JD. Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. *Clinical Breast Cancer* 2007; 7(9): 682–9.
- Schulman KL**, Kohles J. Economic burden of metastatic bone disease in the U.S. *Cancer* 2007; 109(11): 2334–42.
- Wynn ML, **Chang S**, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. *Journal of Women's Health* 2007; 16(7): 971–86.



- Chang S, Long SR**, Kutikova L, Bowman L, **Crown WH**, Lyman GH. Burden of pancreatic cancer and disease progression: Economic analysis in the US. *Oncology* 2006; 70(1): 71–80.
- Kutikova L, Bowman L, **Chang S, Long SR**, Arning M, **Crown WH**. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. *Leukemia & Lymphoma* 2006; 47(8): 1535–44.
- Kutikova L, Bowman L, **Chang S, Long SR**, Obasaju C, **Crown WH**. The economic burden of lung cancer and the associated costs of treatment failure in the United States. *Lung Cancer* 2005; 50(2): 143–154.
- Chang S, Long SR**, Kutikova L, Bowman L, Finley D, **Crown WH**, Bennett CL. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. *Journal of Clinical Oncology* 2004; 22(17): 3524–3530.
- Bradley CJ, Given C, **Baser O**, Gardiner J. Influence of surgical and treatment choices on the cost of breast cancer care. *European Journal of Health Economics* 2003; 4: 96–101.
- Joseph AK, **Mark TL**, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. *Dermatologic Surgery* 2001; 27(11): 955–9.

Respiratory

.....

- Cao Z**, Zou KH, Baker CL, Su J, Paulose-Ram R, **Durden E, Shi N**, Shah H. Respiratory-related medical expenditure and inpatient utilisation among COPD patients receiving long-acting bronchodilator therapy. *Journal of Medical Economics* 2011; 14(2): 147–58.
- Johnston SS, Mark TL**, Dirani R. Smoking cessation: The value of a comprehensive carved-in benefit. *American Journal of Health Promotion* 2008; 23(2): 85–7, ii.
- Brixner DI, **Lenhart G**, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. *Current Medical Research and Opinion* 2007; 23(11): 2887–95.
- Ozminkowski RJ, Wang S, Long SR**. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. *Disease Management and Health Outcomes* 2007; 15(1): 41–55.
- Mucha L, Stephenson J, Morandi N**, Dirani R. Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. *Gender Medicine* 2006; 3(4): 279–91.
- Crown WH**, Berndt ER, **Baser O**, Finkelstein SN, Witt WP, **Maguire J**, Haver KE. Benefit plan design and prescription drug utilization among asthmatics: Do patient copayments matter? *Frontiers in Health Policy Research* 2004; 7: 95–127.
- Orsini L**, Limpa-Amara S, **Crown WH**, Stanford RH, and Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs. montelukast. *Annals of Allergy, Asthma and Immunology* 2004; 92(5): 523–529.



- Crown WH**, Olufade A, **Smith MW**, Nathan R. Seasonal versus perennial allergic rhinitis: Drug and medical resource utilization patterns. *Value in Health* 2003; 6(4): 448–456.
- Crystal-Peters J**, **Neslusan C**, **Crown WH**, **Torres A**. Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma related hospitalizations and emergency room visits. *The Journal of Allergy and Clinical Immunology* 2002; 109(1): 57–62.
- Crystal-Peters J**, **Neslusan CA**, **Smith MW**, **Togias A**. Health care costs of allergic rhinitis-associated conditions vary with allergy season. *Annals of Allergy, Asthma & Immunology* 2002; 89(5): 457–462.
- Merrick NJ**, **Houchens R**, Tillisch S, Berlow B, Landon C. Quality of hospital care of children with asthma: Medicaid versus privately insured patients. *Journal of Health Care for the Poor and Underserved* 2001; 12(2): 192–207.
- Crystal-Peters J**, **Crown WH**, **Goetzel RZ**, **Schutt DC**. The cost of productivity losses associated with allergic rhinitis. *The American Journal of Managed Care* 2000; 6(3): 373–378.
- Ozminkowski R**, **Wang S**, **Marder WD**, **Azzolini J**, **Schutt D**. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. *Pharmacoeconomics* 2000; 18(3): 253–264.

Schizophrenia and Bipolar

- Bagalman E**, Yu-Isenberg KS, **Durden E**, Crivera C, Dirani R, Bunn WB 3rd. Indirect costs associated with nonadherence to treatment for bipolar disorder. *Journal of Occupational and Environmental Medicine* 2010; 52(5): 478–85.
- Durden E**, **Bagalman E**, Muser E, Choi JC, Crivera C, Dirani R, Macfadden W, Haskins JT. Characteristics, healthcare utilization and costs of bipolar disorder type I patients with and without frequent psychiatric intervention in a Medicaid population. *Journal of Medical Economics* 2010; 13(4): 698–704.
- Centorrino F, **Mark TL**, Talamo A, **Oh K**, Chang J. Health and economic burden of metabolic comorbidity among individuals with bipolar disorder. *Journal of Clinical Psychopharmacology* 2009; 29(6): 595–600.
- Citrome L, Reist C, **Palmer L**, **Montejano L**, **Lenhart G**, Cuffel B, Harnett J, Sanders KN. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. *Schizophrenia Research* 2009; 108(1–3): 238–44.
- Citrome L, Reist C, **Palmer L**, **Montejano LB**, **Lenhart G**, Cuffel B, Harnett J, Sanders KN. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. *Schizophrenia Research* 2009; 115(2–3): 115–20.
- Montejano LB**, **Goetzel RZ**, **Ozminkowski RJ**. Impact of bipolar disorder on employers: Rationale for workplace interventions. *Disease Management and Health Outcomes* 2005; 13(4): 267–280.



- Russo PA, Smith MW, Namjoshi M.** Health care costs for schizophrenia patients started on olanzapine versus risperidone. *American Journal of Health-System Pharmacy* 2005; 62(6): 610–615.
- Slade EP, Salkever DS, Rosenheck R, Swanson J, Swartz M, Shern D, Gallucci G, Harding C, **Palmer L, Russo P**, Hough RL, Barrio C, Garcia P. Cost-sharing requirements and access to mental health care among medicare enrollees with schizophrenia. *Psychiatric Services* 2005; 56(8): 960–6.
- Mark TL.** Preferences among antipsychotic medications given particular clinical scenarios. *Schizophrenia Research* 2004; 66(1): 71–73.
- Salkever DS, Slade EP, Karakus M, **Palmer L, Russo PA.** Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. *The Journal of Nervous and Mental Disease* 2004; 192(2): 119–128.
- Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, **Russo PA.** A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. *Schizophrenia Research* 2003; 60(2–3): 259–69.
- Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, **Russo PA, Crown WH.** The schizophrenia care and assessment program health questionnaire (SCAP_HA): An instrument to assess outcomes of schizophrenia care. *Schizophrenia Bulletin* 2003; 29(2): 247–256.
- Mark TL, Palmer LA, Russo PA, Vasey J.** Examination of treatment pattern differences by race. *Mental Health Services Research* 2003; 5(4): 241–250.
- Mark, TL, Dirani R, Slade E, Russo PA.** Access to new medications to treat schizophrenia. *Journal of Behavioral Health Services Research* 2002; 29(1): 15–29.
- Russo P, Smith MW, Dirani R, Namjoshi M, Tohen M.** Pharmacotherapy patterns in the treatment of bipolar disorder. *Bipolar Disorder* 2002; 4(6): 366–377.
- Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T.** Hospitalization and total medical costs for privately insured persons with schizophrenia. *Administration and Policy in Mental Health* 2001; 28(5): 335–351.

Skin Diseases

- White RR, **Lenhart G**, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. *Pharmacoeconomics* 2009; 27(9): 781–92.
- Dworkin RH, White R, O'Connor AB, **Hawkins K.** Health care expenditure burden of persisting herpes zoster pain. *Pain Medicine* 2008; 9(3): 348–53.
- Romanowicz M, Stephenson JJ, Del Rosso JQ, **Lenhart G.** Healthcare utilization and costs of patients with rosacea in an insured population. *Journal of Drugs in Dermatology* 2008; 7(1): 41–9.



Dworkin RH, White R, O'Connor AB, **Baser O**, **Hawkins K**. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. *Journal of the American Geriatrics Society* 2007; 55(8): 1168–75.

Crown WH, Bresnahan BW, **Orsini LS**, **Kennedy S**, Leonardi C. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. *Current Medical Research and Opinion* 2004; 20(12): 1929–1936.

Crown WH. The cost of psoriasis. *Managed Care* 2003; 12(5 Suppl): 10–3.

Substance Abuse

Thomas CP, Garnick DW, Horgan CM, McCorry F, Gmyrek A, Chalk M, Gastfriend DR, Rinaldo SG, Albright J, Capoccia VA, Harris AH, Harwood HJ, Greenberg P, **Mark TL**, Un H, Oros M, Stringer M, Thatcher J, Cotter F, Stein J. Advancing performance measures for use of medications in substance abuse treatment. *Journal of Substance Abuse Treatment* 2011; 40(1): 35–43.

Kranzler HR, **Montejano LB**, Stephenson JJ, **Wang S**, Gastfriend DR. Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population. *Alcoholism, Clinical and Experimental Research* 2010; 34(6): 1090–7.

Mark TL, **Montejano LB**, Kranzler HR, Chalk M, Gastfriend DR. Comparison of healthcare utilization among patients treated with alcoholism medications. *American Journal of Managed Care* 2010; 16(12): 879–88.

Coffey RM, **Levit KR**, **Kassed CA**, McLellan AT, Chalk M, Brady TM, Vandivort-Warren R. Evidence for substance abuse services and policy research: A systematic review of national databases. *Evaluation Review* 2009; 33(2): 103–37.

Mark TL, **Kassed CA**, Vandivort-Warren R, **Levit KR**, Kranzler HR. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. *Drug and Alcohol Dependence* 2009; 99(1-3): 345–9.

Bray J, Vandivort R, Dilonardo J, Dunlap L, **Schroeder D**, **Forhan C**, **Miller K**. Healthcare utilization of individuals with opiate use disorders: An analysis of integrated Medicaid and state mental health/substance abuse agency data. *Journal of Behavioral Health Services & Research* 2008; 35(1): 91–106.

Kranzler HR, Stephenson JJ, **Montejano L**, **Wang S**, Gastfriend DR. Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. *Addiction* 2008; 103(11): 1801–8.

Fowler JS, Volkow ND, **Kassed CA**, Chang L. Imaging the addicted human brain. *Science and Practice Perspectives* 2007; 3(2): 4–16.

Gabel JR, Whitmore H, Pickreign JD, **Levit KR**, **Coffey RM**, Vandivort-Warren R. Substance abuse benefits: Still limited after all these years. *Health Affairs* 2007; 26(4): w474–82.



- Mark TL, Levit KR, Vandivort-Warren R, Coffey RM, Buck JA, the SAMHSA Spending Estimates Team.** Trends in spending for substance abuse treatment, 1986–2003. *Health Affairs* 2007; 26(4): 1118–28.
- Mark TL, Song X, Vandivort R, Duffy S, Butler J, Coffey R, Schabert V.** Characterizing substance abuse programs that treat adolescents. *Journal of Substance Abuse Treatment* 2006; 31(1): 59–65.
- Mark TL, Vandivort-Warren R, Montejano L.** Factors affecting detoxification readmission: Analysis of public sector data from three states. *Journal of Substance Abuse Treatment*. 2006; 31(4): 439–45.
- Mark TL, Coffey RM, Vandivort-Warren R, Harwood HJ, King EC, MHA Spending Estimates Team.** U.S. spending for mental health and substance abuse treatment, 1991–2001. *Health Affairs* 2005; Jan–Jun Suppl Web Exclusives: W5–133–W5–142.
- Mark TL, Swait J.** Using stated preference and revealed preference modeling to evaluate prescribing decisions. *Health Economics* 2004; 13(6): 563–573.
- Mark TL.** Are medications for alcoholism underutilized? An analysis of private sector and Medicaid claims. *Drug Benefit Trends* 2004; 16(3): 154–158.
- Mark TL, Coffey RM.** The decline in receipt of substance abuse treatment by the privately insured, 1992–2001. *Health Affairs* 2004; 23(6): 157–162.
- Mark TL, Coffey RM.** What drove private health insurance spending on mental health and substance abuse care, 1992–1999? *Health Affairs* 2003; 22(1): 165–72.
- Mark TL, Dilonardo JD, Chalk M, Coffey R.** Factors associated with the receipt of treatment following detoxification. *Journal of Substance Abuse Treatment* 2003; 24(4): 299–304.
- Mark TL, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S.** Barriers to the use of medications to treat alcoholism. *American Journal on Addictions* 2003; 12(4): 281–294.
- Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S.** Physicians' opinions about medications to treat alcoholism. *Addiction* 2003; 98(5): 617–626.
- Mark TL, Kranzler HR, Song X.** Understanding US addiction physicians' low rate of naltrexone prescription. *Drug and Alcohol Dependence* 2003; 71(3): 219–228.
- Mark TL, Swait J.** Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. *Value in Health* 2003; 6(4): 474–482.
- Mark TL.** The costs of treating persons with depression and alcoholism compared with depression alone. *Psychiatric Services* 2003; 54(8): 1095–1097.
- Mark TL, Dilonardo JD, Chalk M, Coffey RM.** Trends in detoxification services: 1992–1997. *Journal of Substance Abuse Treatment* 2002; 23(4): 253–260.
- Mark TL, Woody GE, Juday T, Kleber HD.** The economic costs of heroin addiction in the United States. *Drug and Alcohol Dependence* 2001; 61(2): 195–206.



Ozminkowski RJ, Mark T, Cangianelli L, Walsh JM, Davidson R, Blank D, Flegel RR, **Goetzel RZ**. The cost of on-site vs. off-site workplace urinalysis testing for illicit drug use. *Health Care Manager* 2001; 20(1): 59–69.

Dilonardo J, Chalk M, **Mark TL, Coffey RM**, CSAT/CMHS Spending Estimates Team. Recent trends in the financing of substance abuse treatment: Implications for the future. *Health Services Research* 2000; 35(5 Pt 3): 60–71.

Women's Health

Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang SS**, Pohl GM, **Long SR**. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. *Osteoporosis International* 2011; 22(2): 551–7.

Foley K, Foley D, **Johnson BH**. Healthcare resource utilization and expenditures of women diagnosed with hypoactive sexual desire disorder. *Journal of Medical Economics* 2010; 13(4): 583–90.

Lee DW, **Gibson TB, Carls GS, Ozminkowski RJ, Wang S**, Stewart EA. Uterine fibroid treatment patterns in a population of insured women. *Fertility and Sterility* 2009; 91(2): 566–74.

Carls GS, Lee DW, **Ozminkowski RJ, Wang S, Gibson TB**, Stewart E. What are the total costs of surgical treatment for uterine fibroids? *Journal of Women's Health* 2008; 17(7): 1119–32.

Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang S**, Pohl GM, **Long SR**. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. *BMC Women's Health* 2008; 8(1): 24.

Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang S**, Pohl GM, **Long SR**. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. *Osteoporosis International* 2008; 19(3): 373–7.

Sunycz JA, **Mucha L, Baser O**, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. *Osteoporosis International* 2008; 19(10): 1421–9.

Foley KA, Foster SA, Meadows ES, **Baser O, Long SR**. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. *Medical Care* 2007; 45(9): 902–6.

Lee DW, **Ozminkowski RJ, Carls GS, Wang S, Gibson TB**, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. *Journal of Occupational and Environmental Medicine* 2007; 49(5): 493–506.

Rousculp MD, **Long SR, Wang S**, Schoenfeld MJ, Meadows ES. Economic burden of osteoporosis-related fractures in Medicaid. *Value in Health* 2007; 10(2): 144–52.



- Kinchen KS, **Long S, Chang S**, Girts TK, Pantos B. The direct cost of stress urinary incontinence among women in a Medicaid population. *American Journal of Obstetrics & Gynecology* 2005; 193(6): 1936–1944.
- Orsini L**, Rousculp MD, **Long SR, Wang S**. Health care utilization and expenditures in the United States: A study of osteoporosis-related fractures. *Osteoporosis International* 2005; 16: 359–371.
- Kinchen KS, **Orsini L, Crown W**, Bump R. Healthcare utilization among women who undergo surgery for stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2004; 15(3): 154–159.
- Kinchen KS, **Long S, Orsini L, Crown W**, Swindle R. A retrospective claims analysis of the direct costs of stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2003; 14(6): 403–411.
- Chawla A**, Swindle R, **Long S, Kennedy S**, Sternfeld B. Premenstrual dysphoric disorder: Is there an economic burden of illness? *Medical Care* 2002; 40(11): 1101–1112.
- Sternfeld B, Swindle R, **Chawla A, Long S, Kennedy S**. Severity of premenstrual symptoms in a health maintenance organization population. *Obstetrics & Gynecology* 2002; 99(6): 1014–1024.

Other

.....

- Gibson TB**, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. *Health Affairs* 2011; 30(1): 100–8.
- Gibson TB, Wang S, Kelly E, Brown C, Turner C**, Frech-Tamas F, Doyle J, Mauceri E. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. *Health Affairs* 2011; 30(1): 109–17.
- Koehne-Voss S, Schmidli H, **Smith DM**, Pigeot I. The impact of period effects on dose level contrasts in alternating cross-over designs for first-time-in-human studies. *Pharmaceutical Statistics* 2011; 10(1): 45–9.
- O'Malley C, **Johnston SS, Lenhart G**, Cherkowski G, **Palmer L**, Morgan SL. Trends in dual-energy X-ray absorptiometry in the United States, 2000–2009. *Journal of Clinical Densitometry* 2011; (14)2: 100–107.
- Song X, Shi N**, Badamgarav E, Kallich J, **Varker H, Lenhart G**, Curtis JR. Cost burden of second fracture in the US Health System. *Bone* 2011; 48(4): 828–36.
- Chernew M, **Gibson TB**, Fendrick AM. Trends in patient cost sharing for clinical services used as quality indicators. *Journal of General Internal Medicine* 2010; 25(3): 243–8.
- Chernew ME, Sabik LM, Chandra A, **Gibson TB**, Newhouse JP. Geographic correlation between large-firm commercial spending and Medicare spending. *American Journal of Managed Care* 2010; 16(2): 131–8.



- El Khoury AC, Durden E, Ma L, Markson LE, Lee AW, Duan Y, **Foley K**. Perception and management of fever in infants up to six months of age: A survey of US pediatricians. *BMC Pediatrics* 2010; 10(1): 95.
- Kelly BJ, **Fraze TK**, Hornik RC. Response rates to a mailed survey of a representative sample of cancer patients randomly drawn from the Pennsylvania Cancer Registry: A randomized trial of incentive and length effects. *BMC Medical Research Methodology* 2010; 10: 65.
- Owens PL, Barrett ML, **Gibson TB**, Andrews RM, Weinick RM, Mutter RL. Emergency department care in the United States: A profile of national data sources. *Annals of Emergency Medicine* 2010; 56(2): 150–65.
- Pronk NP, **Goetzel RZ**. The practical use of evidence practice and research connected. *American Journal of Preventative Medicine* 2010; 38(2 Suppl): S229–31.
- Stevenson DG, Cohen MA, Tell EJ, **Burwell B**. The complementarity of public and private long-term care coverage. *Health Affairs* 2010; 29(1): 96–101.
- Gibson TB**, Lee TA, Vogeli CS, Hidalgo J, **Carls GS**, **Sredl K**, DesHarnais S, **Marder WD**, Weiss KB, Williams TV, Shields AE. A four-system comparison of patients with chronic illness: The Military Health System, Veterans Health Administration, Medicaid, and commercial plans. *Military Medicine* 2009; 174(9): 936–43.
- Lee DW, **Foster DA**. The association between hospital outcomes and diagnostic imaging: Early findings. *Journal of the American College of Radiology* 2009; 6: 780–785.
- Shi N**, **Foley K**, **Lenhart G**, Badamgarav E. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. *Bone* 2009; 45(6): 1084–90.
- Unruh L, **Russo CA**, Jiang HJ, Stocks C. Can state databases be used to develop a national, standardized hospital nurse staffing database? *Western Journal of Nursing Research* 2009; 31(1): 66–88.
- Baser O**, **Palmer L**, **Stephenson J**. The estimation power of alternative comorbidity indices. *Value in Health* 2008; 11(5): 946–55.
- Chernew M, **Gibson TB**. Cost sharing and HEDIS performance. *Medical Care Research and Review* 2008; 65(6): 713–28.
- Chernew M, **Gibson TB**, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. *Journal of General Internal Medicine* 2008; 23(8): 1131–6.
- Glazer J, McGuire TG, **Cao Z**, Zaslavsky A. Using global rating of health plans to improve the quality of health care. *Journal of Health Economics* 2008; 27(5): 1182–95.
- Houchens RL**, Elixhauser A, Romano P. How often are potential “patient safety events” present on admission? *Joint Commission Journal on Quality and Patient Safety* 2008; 34(3): 154–163.
- Baser O**. Choosing propensity score matching over regression adjustment for causal inference: When, why and how it makes sense. *Journal of Medical Economics* 2007; 10(4): 379–391.



- Baser O.** Modeling transformed health care cost with unknown heteroskedasticity. *Applied Economic Research* 2007; 01: 1–6.
- Baser O.** Using propensity score matching techniques for average treatment effect: Application to triptan use. In *Proceedings of the International Conference on Health Policy Research*, October 28-30 2005, Boston, MA. American Statistical Association; 2007: 4334–4339.
- Lee TA, Shields AE, Vogeli C, **Gibson TB**, Woong-Sohn M, **Marder WD**, Blumenthal D, Weiss KB. Mortality rate in veterans with multiple chronic conditions. *Journal of General Internal Medicine* 2007; 22 Suppl 3: 403–7.
- Thomson Healthcare.** Bad debt, deductions, and utilization by payer. *Healthcare Financial Management* 2007; 61(8): 122–3.
- Turpin RS, **Blumberg PB**, Sharda CE, Salvucci LA, Haggert B, Simmons JB. Patient adherence: Present state and future directions. *Disease Management* 2007; 10(6): 305–10.
- Vogeli C, Shields AE, Lee TA, **Gibson TB**, **Marder WD**, Weiss KB, Blumenthal D. Multiple chronic conditions: Prevalence, health consequences and implications for quality, care management, and costs. *Journal of General Internal Medicine* 2007; 22 Suppl 3: 391–5.
- Zhan C, Elixhauser A, Friedman B, **Houchens R**, Chiang YP. Modifying DRG-PPS to include only diagnoses present on admission: Financial implications and challenges. *Medical Care* 2007; 45(4): 288–91.
- Baser O.** Too much ado about propensity score models? Comparing methods of propensity score matching. *Value in Health* 2006; 9(6): 377–85.
- Baser O, Crown WH**, Pollicino C. Guidelines for selecting among different types of bootstraps. *Current Medical Research and Opinion* 2006; 22(4): 799–808.
- Baser O**, Gardiner JC, Bradley CJ, Yuce H, Given C. Longitudinal analysis of censored medical cost data. *Health Economics* 2006; 15(5): 513–25.
- Coben JH, Steiner CA, Barrett M, **Merrill CT**, **Adamson D**. Completeness of cause of injury coding in healthcare administrative databases in the United States, 2001. *Injury Prevention* 2006; 12(3): 199–201.
- Ozminkowski, RJ, Goetzel RZ, Shechter D**, Stapleton DC, **Baser O**, Lapin P. Predictors of preventive service use among Medicare beneficiaries. *Health Care Financing Review* 2006; 27(3): 5–23.
- Safavi K.** Unintended consequences: Getting the most while avoiding the worst. *Journal of Healthcare Management* 2006; 51(6): 355–9.
- Stallings SC, **Huse D**, Finkelstein SN, **Crown WH**, Witt WP, **Maguire J**, Hiller AJ, Sinskey AJ, Ginsburg GS. A framework to evaluate the economic impact of pharmacogenomics. *Pharmacogenomics* 2006; 7(6): 853–62.
- Coffey RM**, Andrews RM, Moy E. Racial, ethnic, and socioeconomic disparities in estimates of AHRQ patient safety indicators. *Medical Care* 2005; 43(3 Suppl.): I48–57.
- Baker LC, Phibbs CS, Guarino C, **Supina D**. Within-year variation in hospital utilization and its implications for hospital costs. *Journal of Health Economics* 2004; 23: 191–211.



Baser O, Bradley C, Gardiner J, Given B. Estimation from censored medical cost. *Biometrical Journal* 2004; 46: 351–363.

Hansen LG. Is the glass half full or half empty? Patient dynamics underlying marketshare. *Product Management Today* 2004; 15(10): 37–39.

Baser O, Bradley C, Gardiner J, Given B. Testing and correcting non-random selection bias due to censoring: An application to medical costs. *Health Services and Outcomes Research Methodology* 2003; 4(2): 93–107.

Brooks J, Clark MA, **Crown B**, Davey P, Hutchins D, Martin B, Motheral B, Stang P. A checklist for retrospective database studies—Report of the ISPOR Task Force on Retrospective Databases. *Value in Health* 2003; (6)2: 90–97.

Guo JJ, **Curkendall SM**, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. *Pharmacoepidemiology and Drug Safety* 2003; 12(4): 295–301.

Mark TL, **Ozminkowski RJ**, Kirk A, Ettner SL, Drabek J. Risk adjustment for people with chronic conditions in private sector health plans. *Medical Decision Making* 2003; 23(5): 397–405.

Stull DE, Rempher K, Jairath N, Kapustin J. The utility of multidimensional assessments of physical health in patient care. *AACN Clinical Issues* 2003; 14(2): 251–260.

Mark HH, Robbins KP, **Mark TL**. Axial length in applanation tonometry. *Journal of Cataract and Refractive Surgery* 2002; 28(3): 504–6.

Burwell B. Medicaid long-term care expenditures in fiscal year 2000. *Gerontologist* 2001; 41(5): 687–691.

Jones JK, Fife D, **Curkendall SM**, Goehring E, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. *JAMA* 2001; 286(13): 1607–9.

Mark TL, **Coffey RM**. Studying the effects of health plan competition: Are available data resources up to the task? *Health Services Research* 2001; 36(1 Pt 2): 253–275.

To contact Thomson Reuters regarding these and other authored studies, please call +1 866 301 5419 or e-mail marketscan@thomsonreuters.com.